Abstract
NAD(P)H:quinone oxidoreductase 1 (NQO1) is elevated in several human tumors. This study was conducted to determine whether increased levels of NQO1 expression also occur in human pancreatic tumor tissue, and to compare expression levels in nontumorous tissue from smokers with those in nonsmokers. The expression of NQO1 was examined in pancreatic tissue samples from 82 human donors. These samples included normal (n = 20), smokers (n = 25), pancreatitis (n = 7), and adenocarcinomas of the pancreas (n = 30). Genotyping for the C609T polymorphism in NQO1 by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis was also performed. Polymorphic variants were confirmed by automatic sequencing. Higher levels of NQO1 expression were demonstrated in pancreatic adenocarcinomas (0.831 ± 0.021) compared to those in nontumorous tissues from nonsmokers (0.139 ± 0.024). These high levels were also found in smokers (0.729 ± 0.167) and in pancreatitis tissues (0.923 ± 0.184). NQO1 activity was also higher in smokers (2.43 ± 0.61 nmol/min per mg protein) compared to nonsmokers (0.44 ± 0.05 nmol/min per mg protein; p < 0.05). No differences were found in genotype distribution and frequencies of the variant alleles between normal and cancer tissues in this relatively small sample pool. Seventy-five percent of the normal pancreatic tissues showed 609(C/C) and 25% 609(C/T). In pancreatic adenocarcinomas the frequency distribution was 65% C/C, 30% C/T and 5% T/T. The increased expression in noncancer pancreatic tissue from smokers and the fact that smoking is a moderate risk factor for pancreatic cancer suggest that NQO1 expression may be a good candidate as a biomarker for pancreatic cancer, especially in risk groups such as smokers.
Similar content being viewed by others
Abbreviations
- ARE:
-
antioxidant responce element
- NF-κB:
-
nuclear factor-κB
- NQO1:
-
NAD(P) H:quinone oxidoreductase 1
- RT-PCR:
-
reverse transcription–polymerase chain reaction
References
Anderson KE, Hammons GJ, Kadlubar FF, et al. Metabolic activation of aromatic amines by human pancreas. Carcinogenesis. 1997;18:1085–92.
Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastronenterology. 1995;109:247–51.
Bouvet M, Binmoeller KF, Moossa AR. Diagnosis of adenocarcinoma of the pancreas. In: Cameron JL, ed. American Cancer Society atlas of clinical oncology: pancreatic cancer. Hamilton, Ontario: BC Decker;2001.
Chang W-C, Lee Y-C, Liu C-L, et al. Increased expression of iNOS and c-fos via regulation of protein tyrosine phosphorylation and MEK1/ERK2 proteins in terminal bronchiole lesions in the lungs of rats exposed to cigarette smoke. Arch Toxicol. 2001;75:28–35.
Chen H, Lum A, Seifried A, Wilkens LR, Marchand LL. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res. 1999;59:3045–8.
Clairmont A, Sies H, Ramachandran S, et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with the numbers of basal cell carcinomas: use of a multi-variate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis (Lond). 1999;20:1235–40.
De Flora S, Bennicelli C, D'Agostini F, Izzotti A, Camoirano A. Cytosolic activation of aromatic and heterocyclic amines: inhibition by dicoumarol and enhancement in viral hepatitis B. Environ Health Perspect. 1994;6:69–74.
Dhakshinamoorthy S, Long DJ II, Jaiswal AK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cellul Regul. 2000;36:201–6.
Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–92.
Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996;156:2255–60.
Hammons GJ, Warren GJ, Blann E, Nichols J, Lyn-Cook BD. Increased DT-diaphorase activity in transformed and tumorigenic pancreatic acinar cells. Cancer Lett. 1995;96:9–14.
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23–47.
Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76:852–4.
Koudstaal J, Makkink B, Overdiep SH. Enzyme histochemical pattern in human tumours. II. Oxidoreductases in carcinoma of the colon and the breast. Eur J Cancer. 1975;11:111–5.
Landi L, Fiorentini D, Galli MC, Segura-Aguilar J, Beyer RE. DT-diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function. Free Radical Biol Med. 1997;22:329–35.
Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803–7.
Lin Y, Tamakoshi A, Kawamura T, et al. A prospective study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control. 2002;13:249–54.
Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649–57.
Lowry OH, Rosebrough NJ, Farr AL, Randall NJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res. 1992;52:4752–7.
Muller T. Expression of c-fos in quiescent Swiss 3T3 cell exposed to aqueous cigarette smoke fractions. Cancer Res. 1995;55:1927–32.
Nims RW, Prough RA, Lubet RA. Cytosol-mediated reduction of resorufin: a method for measuring quinone oxidoreductase. Arch Biochem Biophys. 1984;229:459–65.
Radjendirane V, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase (NQO1) in cancer cells. In: Oxidative stress and signal transduction. New York: Chapman Hall; 1997: 441–75.
Ross D. Quinone reductases. In: Guengerich FP, Sipes IG, McQueen CA, Gandolfi AJ, eds. Vol. 3. New York: Elsevier; 1997:179–7.
Ross D, Seigel D, Geall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993;12:83–101.
Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H: quinone oxidoreductase polymorphorism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199–206.
Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor form hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997;57:2839–42.
Schlager JJ, Powis G. Cystolic NAD(P)H:(quinone acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45:403–9.
Schor NA, Cornelisse, CJ. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res. 1983;43:4850–5.
Schulz WA, Krumeck A, Rosinger I, et al. Increased frequency of the null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235–9.
Siegel D, Anwar A, Winski SL, Kepa JK, Dowd KL, Ross D. Rapid polyubiquitination proteasomal degradation of a mutant form of NAD(P)H:quinonone oxidoreductase 1. Mol Pharmacol. 2001;59:263–8.
Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P. 609 C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett. 1999;135:67–71.
Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductase1 gene. Proc Natl Acad Sci USA. 1996;93:14960–5.
Vineis P, Caporaso N. Tobacco and cancer epidemiology and the laboratory. Environ Health Perspect. 1995;103:156–60.
Workman P. Enzyme-directed bioreductive drug development revisited. A commentary of recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes particularly DT-diaphorase. Oncol Res. 1994;6: 461–75.
Yao K-S, Hageboutros A., Ford P, O'Dwyer PJ. Involvement of activator protein-1 and nuclear factor-κB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment. Mol Pharmacol. 1997;51:422–30.
Zhu S, Manuel M, Tanaka S, Choe N, Kagan E, Matalon S. Contribution of reactive oxygen and nitrogen species to particulate-induced lung injury. Environ Health Perspect. 1998;106: s1157–63.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lyn-Cook, B.D., Yan-Sanders, Y., Moore, S. et al. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. Cell Biol Toxicol 22, 73–80 (2006). https://doi.org/10.1007/s10565-006-0156-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-006-0156-3